Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly has announced that phase III trial data showed the addition of Gemzar (gemcitabine HCl for injection) to the current standard of care, provided a statistically significant increase in progression-free survival at three years for women with locally advanced cervical cancer.
Subscribe to our email newsletter
The study conducted on 515 patients showed a significant increase in progression-free survival at three years for patients treated with the gemcitabine chemoradiation combination versus those treated only with chemoradiation. Patients on the gemcitabine arm experienced significantly more grade 3/4 toxicities.
Results from this global, multicenter, open-label, randomized Phase III trial were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) during an ASCO-sponsored press conference on May 31, 2009.
Richard Gaynor, Vice President of Cancer Research and Global Oncology Platform Leader for Lilly, said: Lilly continues to look for ways to improve the survival of people living with cancer and fill unmet needs in difficult to treat cancers.